Abstract library

5 results for "Crosara".
#999 Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study
Introduction: Criteria other than RECIST are not validated for evaluation of response during treatment in pancreatic neuroendocrine tumors (pNETs). Preliminary evidence favors antiangiogenic properties of E.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sara Cingarlini
Keywords: everolimus, pNET, P-CT
#1210 Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study.
Introduction: P-CT can evaluate inner perfusional features of primary and metastatic PanNETs; preliminary evidences suggest its potential role in predicting early response to anti-angiogenic therapies. Perfusional modifications induced by E in LM are not completely understood.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1381 [18F]FDG-PET/CT as a Predictive Tool for Response to Chemotherapy and Everolimus Treatment in Patientes with Pancreatic Neuroendocrine Tumour
Introduction: The predictive role of 18F-FDG-PET/CT (FP) in neuroendocrine tumours is debated.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1383 [18F]FDG-PET/CT Heterogeneity in Patients with Metastatic, Well-Differentiated Pancreatic Neuroendocrine Tumours
Introduction: 18F-FDG-PET/CT (FP) often shows an heterogeneous pattern of positivity in patients (P) with pancreatic neuroendocrine tumours (PanNETs).
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1396 3-Drugs Chemotherapy Regimen for G3 PanNENs with Ki67 below 55%: Single Institution Experience
Introduction: To date no standard regimen of chemotherapy (CTH) is universally approved for advanced pancreatic neuroendocrine neoplasms (PanNENs) with Ki67<55% and no predictive selection criteria is available.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Elisabetta Grego